GeloMyrtol could Improve Survival of Patients with Pseudomyxoma Peritonei: A Retrospective Case Control Study on 470 Patients from a Single Center

Abstract

Abstract Background To analyze the clinical efficacy of GeloMyrtol (GM) in treating pseudomyxoma peritonei (PMP). Methods PMP patients treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) at Beijing Shijitan Hospital from July 2015 to April 2022 were included in this study. Patients who took GM before CRS + HIPEC were defined as study group and patients who did not take GM were defined as control group. Kaplan-Meier survival method was used to compare overall survival (OS) of two groups. Univariate and multivariate analyses were performed to identify the independent prognostic factors. Results Among the included 470 PMP patients, 212 (45.1%) cases were in study group and 258 (54.9%) cases in control group. The median OS (mOS) was 156.3 (95%CI: not reached) months in the study group vs. 68.0 (95%CI: 51.9–84.1) months in the control group (P < 0.001). Univariate and multivariate analyses revealed 7 independent prognostic factors: grouping, operation history, histological grading, peritoneal cancer index (PCI), completeness of cytoreduction (CC), lymphatic metastasis and number of resected organs. Patients who did not take GM had a 2.786-fold higher risk of death than those who took GM before CRS + HIPEC (P < 0.001, 95%CI: 0.248–0.519). Conclusions GM could improve survival of PMP treated with CRS + HIPEC.